Journal
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Volume 35, Issue 1, Pages 498-505Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2019.1710502
Keywords
Butyrylcholinesterase; inhibitor; probe; fluorescence
Funding
- Slovenian Research Agency [P1-0208, L1-8157, NC-0009]
- French Ministry of Armed Forces (DGA, SSA)
- Agence Nationale de la Recherche (ANR) [ANR-12-BS07-0008-01]
- France Alzheimer Foundation [FA-AAP-2013-65-101349]
- ESRF [MX1788, MX1992]
- Agence Nationale de la Recherche (ANR) [ANR-12-BS07-0008] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer's disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, reversible, and selective BChE inhibitors, we have developed the fluorescent probes that are selective towards human BChE. The most promising probes also maintain their inhibition of BChE in the low nanomolar range with high selectivity over acetylcholinesterase. Kinetic studies of probes reveal a reversible mixed inhibition mechanism, with binding of these fluorescent probes to both the free and acylated enzyme. Probes show environment-sensitive emission, and additionally, one of them also shows significant enhancement of fluorescence intensity upon binding to the active site of BChE. Finally, the crystal structures of probes in complex with human BChE are reported, which offer an excellent base for further development of this library of compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available